These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

334 related items for PubMed ID: 19450074

  • 1. Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia.
    Ali M, White J, Lee CH, Palmer JL, Smith-Palmer J, Fakhoury W, Valentine WJ.
    J Med Econ; 2008; 11(4):651-70. PubMed ID: 19450074
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
    Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, Valentine WJ.
    Adv Ther; 2008 Aug; 25(8):752-74. PubMed ID: 18704282
    [Abstract] [Full Text] [Related]

  • 3. Cost-effectiveness of switching to biphasic insulin aspart 30 from human insulin in patients with poorly controlled type 2 diabetes in South Korea.
    Lee KH, Seo SJ, Smith-Palmer J, Palmer JL, White J, Valentine WJ.
    Value Health; 2009 Aug; 12 Suppl 3():S55-61. PubMed ID: 20586983
    [Abstract] [Full Text] [Related]

  • 4. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.
    Gupta V, Baabbad R, Hammerby E, Nikolajsen A, Shafie AA.
    J Med Econ; 2015 Apr; 18(4):263-72. PubMed ID: 25426701
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in five European countries.
    Gschwend MH, Aagren M, Valentine WJ.
    J Med Econ; 2009 Jun; 12(2):114-23. PubMed ID: 19545216
    [Abstract] [Full Text] [Related]

  • 6. Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: increased blood pressure and worsened lipid profile partially negate improvements in life expectancy.
    Palmer AJ, Roze S, Valentine WJ, Minshall ME, Lammert M, Nicklasson L, Spinas GA.
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S67-73. PubMed ID: 15324518
    [Abstract] [Full Text] [Related]

  • 7. Acarbose in addition to existing treatments in patients with type 2 diabetes: health economic analysis in a German setting.
    Roze S, Valentine WJ, Evers T, Palmer AJ.
    Curr Med Res Opin; 2006 Jul; 22(7):1415-24. PubMed ID: 16834840
    [Abstract] [Full Text] [Related]

  • 8. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
    St Charles M, Minshall ME, Pandya BJ, Baran RW, Tunis SL.
    Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
    [Abstract] [Full Text] [Related]

  • 9. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H, Kohlmann T, Landgraf W, Holle R, Pirk O, Scholten T.
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [Abstract] [Full Text] [Related]

  • 10. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US.
    Ray JA, Valentine WJ, Roze S, Nicklasson L, Cobden D, Raskin P, Garber A, Palmer AJ.
    Diabetes Obes Metab; 2007 Jan; 9(1):103-13. PubMed ID: 17199725
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China.
    Palmer JL, Beaudet A, White J, Plun-Favreau J, Smith-Palmer J.
    Adv Ther; 2010 Nov; 27(11):814-27. PubMed ID: 21061114
    [Abstract] [Full Text] [Related]

  • 12. A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States.
    Pollock RF, Curtis BH, Valentine WJ.
    J Med Econ; 2012 Nov; 15(4):766-75. PubMed ID: 22413830
    [Abstract] [Full Text] [Related]

  • 13. Health outcomes and economic impact of therapy conversion to a biphasic insulin analog pen among privately insured patients with type 2 diabetes mellitus.
    Cobden D, Lee WC, Balu S, Joshi AV, Pashos CL.
    Pharmacotherapy; 2007 Jul; 27(7):948-62. PubMed ID: 17594200
    [Abstract] [Full Text] [Related]

  • 14. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
    Clements MR, Tits J, Kinsley BT, Råstam J, Friberg HH, Ligthelm RJ.
    Diabetes Obes Metab; 2008 Mar; 10(3):229-37. PubMed ID: 18269638
    [Abstract] [Full Text] [Related]

  • 15. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P, IMPROVE Study Group Expert Panel.
    Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
    [Abstract] [Full Text] [Related]

  • 16. What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE Diabetes Model.
    Palmer AJ, Roze S, Valentine WJ, Minshall ME, Lammert M, Oglesby A, Hayes C, Spinas GA.
    Curr Med Res Opin; 2004 Aug; 20 Suppl 1():S59-66. PubMed ID: 15324517
    [Abstract] [Full Text] [Related]

  • 17. [Health economic consequences of insulin analogues in the treatment of type 1 diabetes in Denmark].
    Palmer AJ, Lammert M, Hermansen K.
    Ugeskr Laeger; 2008 Apr 07; 170(15):1250-4. PubMed ID: 18433583
    [Abstract] [Full Text] [Related]

  • 18. Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.
    Guillermin AL, Lloyd A, Best JH, DeYoung MB, Samyshkin Y, Gaebler JA.
    J Med Econ; 2012 Apr 07; 15(4):654-63. PubMed ID: 22369345
    [Abstract] [Full Text] [Related]

  • 19. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.
    Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, Tucker DM, Foos V, Palmer AJ.
    Curr Med Res Opin; 2007 Mar 07; 23(3):609-22. PubMed ID: 17355742
    [Abstract] [Full Text] [Related]

  • 20. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
    Palmer AJ, Valentine WJ, Chen R, Mehin N, Gabriel S, Bregman B, Rodby RA.
    Nephrol Dial Transplant; 2008 Apr 07; 23(4):1216-23. PubMed ID: 18359872
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.